Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 5:13:267-274.
doi: 10.2147/CCID.S239667. eCollection 2020.

Expert Consensus on Injection Technique and Area-Specific Recommendations for the Hyaluronic Acid Dermal Filler VYC-12L to Treat Fine Cutaneous Lines

Patricia Ogilvie  1 , Jesper Thulesen  2 , Christophe Leys  3 , Dimitris Sykianakis  4 , Jonquille Chantrey  5 , Marva Safa  6 , Vitor Figueiredo  7 , Izolda Heydenrych  8 , Maurizio Cavallini  9 , Elin Kringen Langeland  10 , Anne Wetter  11
Affiliations

Expert Consensus on Injection Technique and Area-Specific Recommendations for the Hyaluronic Acid Dermal Filler VYC-12L to Treat Fine Cutaneous Lines

Patricia Ogilvie et al. Clin Cosmet Investig Dermatol. .

Abstract

Background: VYC-12L is a hyaluronic acid (HA) injectable gel designed to treat fine cutaneous lines and improve skin quality attributes such as hydration and elasticity.

Objective: Expert consensus was sought on VYC-12L injection technique and primary treatment target areas.

Methods: A multinational group of aesthetic medicine clinicians (n = 128) attended product training and each identified ~10 patients for VYC-12L. After treating their first and last patients, the clinicians completed a survey on preferred injection methodology/technique, including injection angle, volume, and spacing. An expert panel (n = 12) discussed survey results and their clinical experiences to obtain consensus on VYC-12L technique and appropriate treatment areas.

Results: Recommendations included micro-depot injections of VYC-12L into the deep dermis with a 32G ½ inch needle inserted at <45º to the skin, spaced 0.5‒1.0 cm apart, with 0.01‒0.05 mL volume per injection (full-face total volume: ~2 mL). Recommended primary treatment areas were the malar, perioral, neck, and décolletage regions. Injection techniques for different treatment areas/demographic characteristics were similar, with some variability in treatment approach. Patient selection criteria, pre- and post-treatment guidelines, and managing patient expectations are important components of treatment.

Conclusion: These consensus recommendations may assist clinicians in optimizing the treatment of fine lines with VYC-12L.

Keywords: Juvéderm Volite; consensus; dermis; hyaluronic acid; injectable dermal filler; skin aging.

PubMed Disclaimer

Conflict of interest statement

P Ogilvie is a consultant, trainer, and principal investigator for Allergan plc, participated in an Allergan Juvéderm Volite advisory board, and received research funding for the clinical registration trial of VYC-12L. M Cavallini, J Chantrey, V Figueiredo, I Heydenrych, E Langeland, M Safa, D Sykianakis, J Thulesen, and A Wetter are investigators for Allergan plc and have participated in an Allergan Juvéderm Volite advisory board. J Chantrey received honorarium from Allergan, during the conduct of the study; honorarium for teaching from Allergan, outside the submitted work. V Figueiredo and E Langeland report personal fees, non-financial support from Allergan, outside the submitted work. I Heydenrych reports personal fees from Allergan, during the conduct of the study; personal fees, non-financial support from Allergan, personal fees from SkinCeuticals, outside the submitted work. C Leys is an investigator for Allergan plc, participated in an Allergan Juvéderm Volite advisory board, and received research funding for the clinical registration trial of VYC-12L. J Thulesen is a consultant for Allergan plc, participated in an Allergan Juvéderm Volite advisory board, and is a faculty member of the Allergan Medical Institute. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Representative images of facial area (A) before treatment and (B) 1 month after injection of VYC-12L into cheek, jawline, and perioral area, 1.0 mL per side. Images courtesy of Jesper Thulesen, MD.
Figure 2
Figure 2
Representative images of décolletage (A) before treatment and (B) 1 month after 1.5-mL injection of VYC-12L. Images courtesy of Patricia Ogilvie, MD.
Figure 3
Figure 3
Representative images of neck (A) before treatment and (B) 1 month after 1.0-mL injection of VYC-12L. Images courtesy of Patricia Ogilvie, MD.
Figure 4
Figure 4
Representative images of cheek (A) before treatment, (B) 1 month after initial injection of VYC-12L, 0.5 mL per side, and (C) 2 weeks after second treatment with VYC-12L, 0.5 mL per side. Images courtesy of Izolda Heydenrych, MD.
See this image and copyright information in PMC

References

    1. Lai M, Oruc I, Barton JJ. The role of skin texture and facial shape in representations of age and identity. Cortex. 2013;49(1):252–265. - PubMed
    1. Tsankova E, Kappas A. Facial skin smoothness as an indicator of perceived trustworthiness and related traits. Perception. 2016;45(4):400–408. doi:10.1177/0301006615616748 - DOI - PubMed
    1. Sutherland CA, Rowley LE, Amoaku UT, et al. Personality judgments from everyday images of faces. Front Psychol. 2015;6:1616. doi:10.3389/fpsyg.2015.01616 - DOI - PMC - PubMed
    1. Jones AL, Kramer RS, Ward R. Signals of personality and health: the contributions of facial shape, skin texture, and viewing angle. J Exp Psychol Hum Percept Perform. 2012;38(6):1353–1361. doi:10.1037/a0027078 - DOI - PubMed
    1. Donofrio L, Carruthers A, Hardas B, et al. Development and validation of a photonumeric scale for evaluation of facial skin texture. Dermatol Surg. 2016;42(suppl 1):S219–S226. doi:10.1097/DSS.0000000000000852 - DOI - PMC - PubMed

LinkOut - more resources